MANDOL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 31m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MANDOL is an injectable small-molecule antibiotic approved by Eli Lilly in 1978 for bacterial infections requiring parenteral therapy. The exact indications are not specified in available data, but the injection route suggests use in acute care or hospital settings. Mechanism of action details are not provided.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on defending market share against generics rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MANDOL represents a defensive, late-lifecycle product with no active hiring pipeline documented. Roles on this brand focus on cost management, generic competition strategy, and customer retention rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on MANDOL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.